Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report

Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Alanzi, Meshaal, Abu-Tineh, Mohammad, Szabados, Lajos, Sharaf Eldean, M Z, Alatasi, Sali, Taha, Ruba Y, Elkourashy, Sarah A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961566/
https://www.ncbi.nlm.nih.gov/pubmed/36852093
http://dx.doi.org/10.2147/OTT.S394193
_version_ 1784895786437312512
author Alanzi, Meshaal
Abu-Tineh, Mohammad
Szabados, Lajos
Sharaf Eldean, M Z
Alatasi, Sali
Taha, Ruba Y
Elkourashy, Sarah A
author_facet Alanzi, Meshaal
Abu-Tineh, Mohammad
Szabados, Lajos
Sharaf Eldean, M Z
Alatasi, Sali
Taha, Ruba Y
Elkourashy, Sarah A
author_sort Alanzi, Meshaal
collection PubMed
description Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt’s lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.
format Online
Article
Text
id pubmed-9961566
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-99615662023-02-26 Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report Alanzi, Meshaal Abu-Tineh, Mohammad Szabados, Lajos Sharaf Eldean, M Z Alatasi, Sali Taha, Ruba Y Elkourashy, Sarah A Onco Targets Ther Case Report Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt’s lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year. Dove 2023-02-21 /pmc/articles/PMC9961566/ /pubmed/36852093 http://dx.doi.org/10.2147/OTT.S394193 Text en © 2023 Alanzi et al. https://creativecommons.org/licenses/by/4.0/This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License. The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Case Report
Alanzi, Meshaal
Abu-Tineh, Mohammad
Szabados, Lajos
Sharaf Eldean, M Z
Alatasi, Sali
Taha, Ruba Y
Elkourashy, Sarah A
Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
title Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
title_full Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
title_fullStr Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
title_full_unstemmed Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
title_short Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
title_sort polatuzumab vedotin in a patient with refractory burkitt lymphoma, a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961566/
https://www.ncbi.nlm.nih.gov/pubmed/36852093
http://dx.doi.org/10.2147/OTT.S394193
work_keys_str_mv AT alanzimeshaal polatuzumabvedotininapatientwithrefractoryburkittlymphomaacasereport
AT abutinehmohammad polatuzumabvedotininapatientwithrefractoryburkittlymphomaacasereport
AT szabadoslajos polatuzumabvedotininapatientwithrefractoryburkittlymphomaacasereport
AT sharafeldeanmz polatuzumabvedotininapatientwithrefractoryburkittlymphomaacasereport
AT alatasisali polatuzumabvedotininapatientwithrefractoryburkittlymphomaacasereport
AT taharubay polatuzumabvedotininapatientwithrefractoryburkittlymphomaacasereport
AT elkourashysaraha polatuzumabvedotininapatientwithrefractoryburkittlymphomaacasereport

Ejemplares similares